• Cancer
  • To evaluate predictors of cardiotoxicity in patients with esophageal cancer treated with trastuzumab and chemoradiation. (clinicaltrials.gov)
  • I. To determine if the addition of trastuzumab to trimodality treatment improves the patient-reported Functional Assessment of Cancer Therapy for Esophageal Cancer (FACT-E) Esophageal Cancer Subscale (ECS) score. (clinicaltrials.gov)
  • intravenous
  • According to updated results of the HannaH study published in the journal Annals of Oncology, researchers have found that subcutaneous trastuzumab has a similar safety profile and similar event-free survival rate with intravenous trastuzumab. (oncologynurseadvisor.com)
  • According to the results of the present study, the safety profile of subcutaneous (s.c.) trastuzumab was consistent with the previously published data from HannaH and the known safety profile of intravenous (i.v.) trastuzumab. (oncologynurseadvisor.com)